Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN010
MIFTS: 56

Urinary Tract Obstruction

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary Tract Obstruction

About this section

MalaCards integrated aliases for Urinary Tract Obstruction:

Name: Urinary Tract Obstruction 12 15 73
Obstructive Uropathy 12 55
Urinary Obstruction 12
Urologic Diseases 73

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:5200
ICD10 33 N13.9
ICD9CM 35 599.6 599.60
NCIt 50 C3675 C79805
Sources

Summaries for Urinary Tract Obstruction

About this section
MalaCards based summary : Urinary Tract Obstruction, also known as obstructive uropathy, is related to cystitis and pyelonephritis, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary Tract Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and p70S6K Signaling. The drugs Tamsulosin and Adrenergic Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and bone, and related phenotypes are growth/size/body region and homeostasis/metabolism

Sources

Related Diseases for Urinary Tract Obstruction

About this section

Diseases related to Urinary Tract Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 126)
# Related Disease Score Top Affiliating Genes
1 cystitis 30.7 EGF HBEGF PTGS2 UMOD
2 pyelonephritis 30.3 ALB CCL2 NAGLU UMOD
3 vesicoureteral reflux 1 30.2 NAGLU REN UMOD
4 hydronephrosis 28.7 ALB AQP2 B2M CCL2 EGF NAGLU
5 kidney disease 26.1 ALB AQP2 B2M CCL2 NAGLU PKDREJ
6 pelvic lipomatosis 11.2
7 congenital anomalies of kidney and urinary tract 2 11.0
8 small cell carcinoma of the bladder 10.8
9 adult hepatocellular carcinoma 10.8 EGF PIK3CA
10 interstitial cystitis 10.7 EGF HBEGF UMOD
11 acute kidney tubular necrosis 10.7 ALB NAGLU UMOD
12 tuberculous meningitis 10.7 CCL2 GGT1 TGFB1
13 lipoid nephrosis 10.7 ALB CCL2 NAGLU
14 end stage renal failure 10.6 ALB TGFB1 UMOD
15 prostate transitional cell carcinoma 10.6 KLK3 PIK3CA
16 respiratory system disease 10.6 ALB CCL2 TGFB1
17 acute cystitis 10.6 ALB CCL2 KLK3
18 immunodeficiency 43 10.6 ALB B2M
19 peyronie's disease 10.5 CCL2 SMAD3 TGFB1
20 prostate adenoid cystic carcinoma 10.5 KLK3 PIK3CA
21 peritonitis 10.4 ALB B2M CCL2
22 benign essential hypertension 10.4 ALB REN
23 interstitial nephritis 10.4 ALB REN UMOD
24 fanconi-like syndrome 10.4 B2M PTGS2
25 prostate squamous cell carcinoma 10.4 B2M KLK3 PIK3CA
26 membranous nephropathy 10.4 ALB B2M TGFB1
27 penile disease 10.3 SMAD2 SMAD3 TGFB1
28 hypertrophic scars 10.3 SMAD2 SMAD3 TGFB1
29 leukoregulin 10.3 PTGS2 TGFB1
30 keloids 10.3 SMAD2 SMAD3 TGFB1
31 hepatitis b 10.3 ALB GGT1 PIK3CA TGFB1
32 chagas disease 10.3 CCL2 SMAD2 TGFB1
33 kidney hypertrophy 10.3 ALB CTGF TGFB1
34 orthostatic proteinuria 10.3 ALB B2M REN
35 gastrointestinal system cancer 10.3 ALB PIK3CA PTGS2
36 ureteral obstruction 10.3 AQP2 PTGS2 TGFB1
37 obstructive jaundice 10.3 ALB GGT1 REN
38 idiopathic hypercalciuria 10.3 NAGLU REN SLPI
39 nephrosclerosis 10.3 CCL2 CTGF TGFB1
40 arteries, anomalies of 10.2 ALB CCL2 REN
41 sialolithiasis 10.2 ALB CTGF TGFB1
42 vitreoretinopathy, neovascular inflammatory 10.2 CCL2 CTGF TGFB1
43 adamantinoma of long bones 10.2 EGF KLK3 PIK3CA PTGS2
44 idiopathic interstitial pneumonia 10.2 CCL2 CTGF TGFB1
45 biliary atresia 10.2 ALB CTGF TGFB1
46 urethritis 10.1
47 acquired metabolic disease 10.1 ALB CCL2 REN
48 clear cell adenocarcinoma 10.1 KLK3 SMAD2 SMAD3
49 pauci-immune glomerulonephritis 10.1 CTGF SMAD2
50 gastrointestinal system disease 10.1 ALB GGT1 PTGS2

Comorbidity relations with Urinary Tract Obstruction via Phenotypic Disease Network (PDN): (show all 21)


Acute Cystitis Acute Kidney Failure
Bladder Cancer Bladder Neck Obstruction
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hydronephrosis Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Paralytic Ileus
Prostate Calculus Prostate Cancer
Prostatic Hypertrophy Prostatitis
Protein-Energy Malnutrition Ureterolithiasis
Urethral Stricture

Graphical network of the top 20 diseases related to Urinary Tract Obstruction:



Diseases related to Urinary Tract Obstruction
Sources

Symptoms & Phenotypes for Urinary Tract Obstruction

About this section

UMLS symptoms related to Urinary Tract Obstruction:


dysuria, polyuria, urgency of micturition, pain in urethra, renal colic, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, uti symptoms, bladder discomfort, renal pain, other and unspecified genitourinary symptoms, urologic problem

MGI Mouse Phenotypes related to Urinary Tract Obstruction:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 AQP2 EGF B2M GGT1 HBEGF CTGF
2 homeostasis/metabolism MP:0005376 10.35 AQP2 B2M GGT1 CTGF ALB PTGS2
3 behavior/neurological MP:0005386 10.33 AQP2 GGT1 HBEGF PTGS2 NAGLU REN
4 immune system MP:0005387 10.3 EGF B2M GGT1 CCL2 NAGLU REN
5 cardiovascular system MP:0005385 10.28 CTGF B2M HBEGF PTGS2 NAGLU REN
6 endocrine/exocrine gland MP:0005379 10.25 CTGF ALB EGF B2M GGT1 PTGS2
7 mortality/aging MP:0010768 10.24 ALB AQP2 B2M GGT1 CTGF PTGS2
8 integument MP:0010771 10.21 AQP2 EGF B2M GGT1 HBEGF CTGF
9 digestive/alimentary MP:0005381 10.18 CTGF ALB EGF B2M PTGS2 SLC5A6
10 liver/biliary system MP:0005370 10.06 CTGF ALB B2M PTGS2 NAGLU SMAD3
11 renal/urinary system MP:0005367 9.96 AQP2 GGT1 ALB PTGS2 NAGLU REN
12 reproductive system MP:0005389 9.9 EGF AQP2 B2M GGT1 PTGS2 REN
13 neoplasm MP:0002006 9.87 ALB B2M PTGS2 PIK3CA SMAD3 SMAD2
14 skeleton MP:0005390 9.7 GGT1 CTGF PTGS2 NAGLU PIK3CA HBEGF
15 vision/eye MP:0005391 9.28 CTGF EGF GGT1 PTGS2 NAGLU PIK3CA
Sources

Drugs & Therapeutics for Urinary Tract Obstruction

About this section

Drugs for Urinary Tract Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 106133-20-4 129211
2 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
3 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
4 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
5 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
7 Tolterodine tartrate Phase 4 124937-52-6
8 Cholinergic Agents Phase 4
9 Muscarinic Antagonists Phase 4
10 Cholinergic Antagonists Phase 4
11
Indomethacin Approved, Investigational Phase 3 53-86-1 3715
12
Artesunate Approved, Investigational Phase 3 88495-63-0 6917864 5464098
13
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
14
Acetaminophen Approved Phase 3 103-90-2 1983
15
Lumefantrine Approved Phase 3 82186-77-4 6437380
16
Artemether Approved Phase 3 71963-77-4 119380 68911
17 Analgesics Phase 3
18 Natriuretic Agents Phase 3
19 Coagulants Phase 3
20 Cyclooxygenase Inhibitors Phase 3
21 Hemostatics Phase 3
22 Analgesics, Non-Narcotic Phase 3
23 Tocolytic Agents Phase 3
24 Deamino Arginine Vasopressin Phase 3
25 Vasopressins Phase 3
26 Peripheral Nervous System Agents Phase 3
27 Anti-Bacterial Agents Phase 3
28 Antibiotics, Antitubercular Phase 3
29 Anti-Infective Agents Phase 3,Phase 1
30 Anti-Inflammatory Agents Phase 3,Phase 2
31 Anti-Inflammatory Agents, Non-Steroidal Phase 3
32 Arginine Vasopressin Phase 3
33 Antirheumatic Agents Phase 3
34 Anthelmintics Phase 3
35 Antifungal Agents Phase 3
36 Antiparasitic Agents Phase 3
37 Antiprotozoal Agents Phase 3
38 Antipyretics Phase 3
39 Antimalarials Phase 3
40 Artemether-lumefantrine combination Phase 3
41 Artemisinine Phase 3
42 Artemisinins Phase 3
43 arginine Nutraceutical Phase 3
44 carnitine Nutraceutical Phase 3
45 Omega 3 Fatty Acid Nutraceutical Phase 3
46
Pancuronium Approved Phase 2 15500-66-0 27350 441289
47
Tamoxifen Approved Phase 2 10540-29-1 2733526
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2 437-38-7 3345
49
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
50
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Functional MR Urography Completed NCT00301470 Phase 4
2 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
3 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
4 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
5 Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic Unknown status NCT01742689 Phase 3 Desmopressin intranasal spray;Placebo intranasal spray;Indomethacin suppository
6 Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence Unknown status NCT02112591 Phase 3
7 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3 Omexel;spasfon
8 Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria Recruiting NCT03056391 Phase 3 Paracetamol
9 Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions Unknown status NCT01552824 Phase 2
10 Prednisone Versus Tamoxifen in Idiopathic Retroperitoneal Fibrosis Unknown status NCT00440349 Phase 2 Tamoxifen;Prednisone
11 Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed NCT01718353 Phase 2 DOCETAXEL (XRP6976);CABAZITAXEL (XRP6258);Prednisone
12 Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms Completed NCT02244281 Phase 2 tamsulosin hydrochloride;Placebo
13 Bipolar Androgen-based Therapy for Prostate Cancer (BAT) Completed NCT01750398 Phase 2 Testosterone cypionate;Goserelin;Leuprolide
14 Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Completed NCT00527488 Phase 2 Degarelix;Degarelix;Degarelix;Degarelix
15 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
16 ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. Recruiting NCT02933801 Phase 2 ODM-201
17 Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery Not yet recruiting NCT03541850 Phase 2 Antiandrogen Therapy
18 Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Terminated NCT01919346 Phase 2 Eculizumab;Normal Saline
19 A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma Completed NCT00315731 Phase 1
20 Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria Unknown status NCT02139059 Not Applicable
21 Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment Completed NCT03280420 Not Applicable
22 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877 Not Applicable
23 Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage Completed NCT02055430 Not Applicable
24 Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) Completed NCT02398682 Not Applicable
25 Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men Completed NCT02330107 Not Applicable
26 Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO) Recruiting NCT03281798 Not Applicable
27 Standardized Prenatal Clinical Care for LUTO Recruiting NCT02315521
28 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia Recruiting NCT03055624 Not Applicable
29 Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate Recruiting NCT03034187
30 Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate Recruiting NCT03157726 Not Applicable
31 Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer Active, not recruiting NCT03104907 Not Applicable
32 Green LEP vs ThuLEP vs HoLEP in Management of Marked Enlarged Prostate Active, not recruiting NCT03305861 Not Applicable
33 Indwelling Stent Discoloration Project Active, not recruiting NCT02007980
34 Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence Enrolling by invitation NCT02578056 Not Applicable
35 Fetal Cystoscopy for Lower Urinary Tract Obstruction Terminated NCT02446184 Not Applicable
36 Tc-99m Renography and Cisplatin-induced Nephrotoxicity Terminated NCT00213642
37 Functional, Dynamic, and Anatomic MR Urography Withdrawn NCT00585767

Search NIH Clinical Center for Urinary Tract Obstruction

Sources

Genetic Tests for Urinary Tract Obstruction

About this section
Sources

Anatomical Context for Urinary Tract Obstruction

About this section

MalaCards organs/tissues related to Urinary Tract Obstruction:

41
Prostate, Kidney, Bone, Testes, Lung, Smooth Muscle, Neutrophil
Sources

Publications for Urinary Tract Obstruction

About this section

Articles related to Urinary Tract Obstruction:

(show top 50) (show all 357)
# Title Authors Year
1
Perinatal Outcomes of Fetal Lower Urinary Tract Obstruction After Vesicoamniotic Shunting Using a Double-Basket Catheter. ( 29498072 )
2018
2
Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )
2018
3
Current State of Fetal Intervention for Lower Urinary Tract Obstruction. ( 29468448 )
2018
4
Comparison of biochemical analysis of fetal serum and fetal urine in the prediction of postnatal renal outcome in lower urinary tract obstruction. ( 29644715 )
2018
5
Successful medical management of pseudomembranous cystitis in three cats with lower urinary tract obstruction. ( 29226304 )
2018
6
SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. ( 29852947 )
2018
7
Long-term renal outcome in infants with congenital lower urinary tract obstruction. ( 29980359 )
2018
8
A classic twin study of lower urinary tract obstruction: Report of 3 cases and literature review. ( 29664229 )
2018
9
Antenatal staging of congenital lower urinary tract obstruction. ( 29978555 )
2018
10
The Uroplakin Plaque Promotes Renal Structural Integrity During Congenital and Acquired Urinary Tract Obstruction. ( 29897287 )
2018
11
Three-dimensional virtual cystoscopy: Noninvasive approach for the assessment of urinary tract in fetuses with lower urinary tract obstruction. ( 29178428 )
2017
12
Complete upper urinary tract obstruction caused by penetrating pellet injury of the ureterintroduction. ( 28513528 )
2017
13
Can bladder fibrosis in congenital urinary tract obstruction be reversed? ( 29037864 )
2017
14
Natural History of Fetal Lower Urinary Tract Obstruction with Normal Amniotic Fluid Volume at Initial Diagnosis. ( 28700992 )
2017
15
Forkhead box O3 (FoxO3) regulates kidney tubular autophagy following urinary tract obstruction. ( 28705935 )
2017
16
Influence of bladder fullness on the detection of urinary tract obstruction by dynamic renal scintigraphy. ( 28894331 )
2017
17
Ultrasound guided balloon catheterisation: a new method of fetal lower urinary tract obstruction management. ( 28580571 )
2017
18
Early vesico-amniotic shunting - does it change the prognosis in fetal lower urinary tract obstruction diagnosed in the first trimester? ( 29057434 )
2017
19
Fetal surgery for lower urinary tract obstruction: the importance of staging prior to intervention. ( 29160637 )
2017
20
Lower urinary tract obstruction: fetal intervention based on prenatal staging. ( 28730376 )
2017
21
Spontaneous rupture of the renal pelvis caused by upper urinary tract obstruction: A case report and review of the literature. ( 29390332 )
2017
22
Diagnostic value of 64-slice spiral computed tomography imaging of the urinary tract during the excretory phase for urinary tract obstruction. ( 29201177 )
2017
23
Urinary tract obstruction: Stem cells hinder stricture formation. ( 27349369 )
2016
24
Analysis of Preoperative Urinary Tract Obstruction in Patients with Scoliosis. ( 27507671 )
2016
25
Two-year outcomes after diagnostic and therapeutic fetal cystoscopy for lower urinary tract obstruction. ( 26739350 )
2016
26
Anterior Urethral Valve: A Rare But an Important Cause of Infravesical Urinary Tract Obstruction. ( 27231492 )
2016
27
Urinary tract obstruction: NLRP3 inhibition prevents BOO. ( 26754189 )
2016
28
Sequential fetal serum I^2-microglobulin to predict postnatal renal function in bilateral or low urinary tract obstruction. ( 27197901 )
2016
29
Effectiveness of vesico-amniotic shunt in fetuses with congenital lower urinary tract obstruction: An updated systematic review and meta-analysis. ( 27270578 )
2016
30
Vesico-amniotic shunting for lower urinary tract obstruction in a fetus with VACTERL association. ( 27061706 )
2016
31
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
32
Lower urinary tract obstruction in male children - a report of three cases. ( 27622420 )
2016
33
Fetal Serum I^2-Microglobulin and Postnatal Renal Function in Lower Urinary Tract Obstruction Treated with Vesicoamniotic Shunt. ( 27603215 )
2016
34
EP21.11: Prediction of shunt dislodgement in fetuses with lower urinary tract obstruction. ( 27646514 )
2016
35
Are ultrasound renal aspects associated with urinary biochemistry in fetuses with lower urinary tract obstruction? ( 27862070 )
2016
36
Factors associated with fetal shunt dislodgement in lower urinary tract obstruction. ( 27247093 )
2016
37
Outcome in fetal lower urinary tract obstruction: a prospective registry. ( 25689128 )
2015
38
Congenital urinary tract obstruction: the long view. ( 26088076 )
2015
39
Fetal Lower Urinary Tract Obstruction - A proposal of Standardized Multidisciplinary Prenatal Management based on Disease Severity. ( 26690832 )
2015
40
Current applications of in utero intervention for lower urinary tract obstruction. ( 26441047 )
2015
41
Fetal Lower Urinary Tract Obstruction (LUTO): a practical review for providers. ( 27057343 )
2015
42
Defining and predicting 'intrauterine fetal renal failure' in congenital lower urinary tract obstruction. ( 26525197 )
2015
43
Re: Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesicoamniotic shunting. R. Ruano, N. Sananes, H. Sangi-Haghpeykar, S. Hernandez-Ruano, R. Moog, F. Becmeur, A. Zaloszyc, A. M. Giron, B. Morin and R. Favre. Ultrasound Obstet Gynecol 2015; 45: 452-458. ( 25833370 )
2015
44
Postobstructive diuresis in cats with naturally occurring lower urinary tract obstruction: incidence, severity and association with laboratory parameters on admission. ( 26179575 )
2015
45
Fetal intervention for severe lower urinary tract obstruction: a multicenter case-control study comparing fetal cystoscopy with vesico-amniotic shunting. ( 25157756 )
2014
46
Lower urinary tract obstruction in the fetus and neonate. ( 25155733 )
2014
47
Pathological feature and immunoprofile of cystitis glandularis accompanied with upper urinary tract obstruction. ( 25136635 )
2014
48
Palliative management of malignant upper urinary tract obstruction. ( 26052193 )
2014
49
Fetal urine biochemistry at 13-23 weeks in low urinary tract obstruction: criteria for in utero treatment. ( 25412852 )
2014
50
The experience of pregnant women with a diagnosis of fetal lower urinary tract obstruction (LUTO). ( 24290423 )
2013
Sources

Variations for Urinary Tract Obstruction

About this section
Sources

Expression for Urinary Tract Obstruction

About this section
Search GEO for disease gene expression data for Urinary Tract Obstruction.
Sources

Pathways for Urinary Tract Obstruction

About this section

Pathways related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 66
Show member pathways
 13.3 B2M CCL2 EGF HBEGF PIK3CA PTGS2
2
p70S6K Signaling 64
Show member pathways
 12.98 CCL2 CTGF EGF HBEGF PTGS2 REN
3
Endometrial cancer 37
Show member pathways
 12.8 EGF KLK3 PIK3CA SMAD2 SMAD3 TGFB1
4
Gastric cancer 37
Show member pathways
 12.71 EGF PIK3CA SMAD2 SMAD3 TGFB1
5
Pathways in cancer 37
12.63 EGF KLK3 PIK3CA PTGS2 SMAD2 SMAD3
6
ErbB signaling pathway 1 37
Show member pathways
 12.42 EGF HBEGF PIK3CA TGFB1
7
Development EGFR signaling pathway 22
Show member pathways
 12.4 EGF HBEGF PIK3CA SMAD2 SMAD3 TGFB1
8
HTLV-I infection 37
12.37 PIK3CA SMAD2 SMAD3 TGFB1
9
Folate Metabolism 1
Show member pathways
 12.26 ALB CCL2 GGT1 PTGS2
10
Proteoglycans in cancer 37
12.22 HBEGF PIK3CA SMAD2 TGFB1
11
Wnt / Hedgehog / Notch 4
12.17 CTGF SMAD2 SMAD3 TGFB1
12
Cellular senescence (KEGG) 37
12.1 PIK3CA SMAD2 SMAD3 TGFB1
13
Hippo signaling pathway 37
12.08 CTGF SMAD2 SMAD3 TGFB1
14
Colorectal Cancer Metastasis 64
12.07 EGF PTGS2 SMAD2 SMAD3 TGFB1
15
NRF2 pathway 1
12.05 GGT1 HBEGF SLC5A6 TGFB1
16
TGF-beta Signaling Pathways 65
11.82 SMAD2 SMAD3 TGFB1
17
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.81 SMAD2 SMAD3 TGFB1
18
FoxO signaling pathway 37
Show member pathways
 11.79 EGF PIK3CA SMAD2 SMAD3 TGFB1
19
TGF-beta signaling pathway (KEGG) 37
11.76 SMAD2 SMAD3 TGFB1
20
Angiogenesis (CST) 4
11.76 CCL2 PTGS2 REN TGFB1
21
Loss of Function of SMAD2/3 in Cancer 66
Show member pathways
 11.71 SMAD2 SMAD3 TGFB1
22
Development_TGF-beta receptor signaling 22
11.67 SMAD2 SMAD3 TGFB1
23
TGF-beta receptor signaling activates SMADs 66
Show member pathways
 11.65 SMAD2 SMAD3 TGFB1
24
Regulation of Telomerase 1
11.62 EGF SMAD3 TGFB1
25
Lung fibrosis 1
11.58 CCL2 CTGF EGF TGFB1
26
AGE-RAGE signaling pathway in diabetic complications 37
11.55 CCL2 PIK3CA SMAD2 SMAD3 TGFB1
27
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.51 CCL2 CTGF EGF PIK3CA SMAD2 SMAD3
28
Hepatitis C and Hepatocellular Carcinoma 1
11.49 PTGS2 SMAD3 TGFB1
29
TGF-beta Receptor Signaling (WikiPathways) 1
11.47 EGF SMAD2 SMAD3 TGFB1
30
IL-2 Gene Expression in Activated and Quiescent T-Cells 64
Show member pathways
 11.41 SMAD2 SMAD3 TGFB1
31
TGF-beta receptor signaling (Pathway Interaction Database) 1
11.33 CTGF SMAD2 SMAD3 TGFB1
32
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.26 EGF HBEGF KLK3 PIK3CA SMAD3 TGFB1
33
Extracellular vesicle-mediated signaling in recipient cells 1
11.22 SMAD2 SMAD3 TGFB1
34
Hypothesized Pathways in Pathogenesis of Cardiovascular Disease 1
11.11 CTGF SMAD2 SMAD3
35
IL1 and megakaryocytes in obesity 1
11.1 CCL2 HBEGF PIK3CA
36
TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition 1
10.93 SMAD2 SMAD3 TGFB1
Sources

GO Terms for Urinary Tract Obstruction

About this section

Cellular components related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 ALB B2M CCL2 CTGF EGF HBEGF
2 platelet alpha granule lumen GO:0031093 9.43 ALB EGF TGFB1
3 extracellular space GO:0005615 9.36 ALB B2M CCL2 CTGF EGF GGT1
4 SMAD protein complex GO:0071141 9.32 SMAD2 SMAD3
5 heteromeric SMAD protein complex GO:0071144 9.16 SMAD2 SMAD3

Biological processes related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 PTGS2 SMAD2 SMAD3 TGFB1 UMOD
2 MAPK cascade GO:0000165 9.97 CCL2 EGF HBEGF TGFB1
3 positive regulation of gene expression GO:0010628 9.97 CTGF EGF SMAD2 SMAD3 TGFB1
4 cell migration GO:0016477 9.95 CTGF HBEGF PIK3CA TGFB1
5 positive regulation of cell migration GO:0030335 9.9 EGF HBEGF SMAD3 TGFB1
6 response to estradiol GO:0032355 9.86 CTGF PTGS2 TGFB1
7 response to organic substance GO:0010033 9.86 PTGS2 REN TGFB1
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.85 SMAD2 SMAD3 TGFB1
9 positive regulation of protein kinase B signaling GO:0051897 9.85 EGF HBEGF PIK3CA TGFB1
10 wound healing GO:0042060 9.84 SMAD2 SMAD3 TGFB1
11 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 EGF HBEGF TGFB1
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.83 PIK3CA PTGS2 TGFB1
13 response to glucose GO:0009749 9.82 CTGF SMAD2 TGFB1
14 cell chemotaxis GO:0060326 9.81 CCL2 HBEGF PIK3CA
15 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.79 SMAD2 SMAD3 TGFB1
16 SMAD protein signal transduction GO:0060395 9.76 SMAD2 SMAD3 TGFB1
17 angiogenesis GO:0001525 9.72 CCL2 CTGF EGF PIK3CA PTGS2
18 protein kinase B signaling GO:0043491 9.71 CCL2 PIK3CA TGFB1
19 positive regulation of epithelial to mesenchymal transition GO:0010718 9.7 SMAD2 SMAD3 TGFB1
20 ureteric bud development GO:0001657 9.69 SMAD2 SMAD3 TGFB1
21 negative regulation of ERBB signaling pathway GO:1901185 9.68 EGF HBEGF
22 zymogen activation GO:0031638 9.67 GGT1 KLK3
23 lens fiber cell differentiation GO:0070306 9.66 SMAD3 TGFB1
24 ERBB2 signaling pathway GO:0038128 9.65 EGF HBEGF PIK3CA
25 response to cholesterol GO:0070723 9.63 SMAD2 TGFB1
26 nodal signaling pathway GO:0038092 9.63 SMAD2 SMAD3
27 endoderm development GO:0007492 9.63 SMAD2 SMAD3 TGFB1
28 primary miRNA processing GO:0031053 9.62 SMAD2 SMAD3
29 pericardium development GO:0060039 9.61 SMAD2 SMAD3
30 embryonic foregut morphogenesis GO:0048617 9.61 SMAD2 SMAD3
31 positive regulation of protein import into nucleus GO:0042307 9.61 PTGS2 SMAD3 TGFB1
32 common-partner SMAD protein phosphorylation GO:0007182 9.57 SMAD2 TGFB1
33 regulation of striated muscle tissue development GO:0016202 9.56 SMAD3 TGFB1
34 positive regulation of extracellular matrix assembly GO:1901203 9.49 SMAD3 TGFB1
35 epidermal growth factor receptor signaling pathway GO:0007173 9.46 EGF HBEGF PIK3CA TGFB1
36 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.43 SMAD2 SMAD3 TGFB1
37 evasion or tolerance of host defenses by virus GO:0019049 9.4 SMAD3 TGFB1
38 paraxial mesoderm morphogenesis GO:0048340 9.37 SMAD2 SMAD3
39 SMAD protein complex assembly GO:0007183 9.13 SMAD2 SMAD3 TGFB1
40 regulation of binding GO:0051098 8.8 SMAD2 SMAD3 TGFB1
41 positive regulation of cell proliferation GO:0008284 10.06 CTGF EGF HBEGF PTGS2 TGFB1

Molecular functions related to Urinary Tract Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGF HBEGF PIK3CA
2 growth factor activity GO:0008083 9.46 CTGF EGF HBEGF TGFB1
3 co-SMAD binding GO:0070410 9.4 SMAD2 SMAD3
4 type I transforming growth factor beta receptor binding GO:0034713 9.37 SMAD2 TGFB1
5 primary miRNA binding GO:0070878 9.26 SMAD2 SMAD3
6 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 8.96 SMAD2 SMAD3
7 transforming growth factor beta receptor binding GO:0005160 8.8 SMAD2 SMAD3 TGFB1
Sources

Sources for Urinary Tract Obstruction

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....